The U.S. Food and Drug Administration has approved AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) for both the ...

Final results of a randomized phase II/III study comparing perioperative adriamycin plus ifosfamide and gemcitabine plus docetaxel for high-grade soft tissue sarcomas: Japan Clinical Oncology Group ...

Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But ...

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...

A study published inClinical Cancer Research found that in patients with unresectable, locally advanced esophageal cancer, the triple combination of radiation, chemotherapy, and immunotherapy made ...

Patients who fasted during chemotherapy for ovarian cancer had significantly longer progression-free survival (PFS) compared ...

Six weeks of neoadjuvant chemotherapy for patients with operable colon cancer is safe and results in downstaging, increased complete resection rates, and better disease control at 2 years, according ...

Three-year survival data from a phase 2 trial of neoadjuvant short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. This is an ASCO Meeting Abstract ...

Depending on the disease specifics, patients with melanoma may undergo pre- or post-surgical therapies. Skin melanoma, one of the most serious forms of skin cancer, poses a significant threat to ...

Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among ...